2008 - Intensive insulin therapy and starch (HES 200/0.5) had some risk and no clear benefit in severe sepsis
- Effects of hydroxyethyl starch in subgroups of patients with severe sepsis: exploratory post-hoc analyses of a randomised trial. Müller, Rasmus; Haase, Nicolai; Wetterslev, Jørn; Perner, Anders // Intensive Care Medicine;Nov2013, Vol. 39 Issue 11, p1963
Purpose: It has been speculated that certain subgroups of sepsis patients may benefit from treatment with hydroxyethyl starch (HES) 130/0.42, specifically in the earlier resuscitation of patients with more severely impaired circulation. Methods: This was a post-hoc, subgroup analysis of all 798...
- Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Haase, Nicolai; Wetterslev, Jørn; Winkel, Per; Perner, Anders // Intensive Care Medicine;Dec2013, Vol. 39 Issue 12, p2126
Purpose: We aimed to characterize the degree and clinical importance of bleeding in patients treated with hydroxyethyl starch (HES). Methods: In post hoc analyses, we examined the associations between fluid assignment, hemostatic variables, bleeding events, transfusions, and death among 798...
- Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis. Perner, Anders; Haase, Nicolai; Guttormsen, Anne B.; Tenhunen, Jyrki; Klemenzson, Gudmundur; �neman, Anders; Madsen, Kristian R.; M�ller, Morten H.; Elkj�r, Jeanie M.; Poulsen, Lone M.; Bendtsen, Asger; Winding, Robert; Steensen, Morten; Berezowicz, Pawel; S�e-Jensen, Peter; Bestle, Morten; Strand, Kristian; Wiis, J�rgen; White, Jonathan O.; Thornberg, Klaus J. // New England Journal of Medicine;7/12/2012, Vol. 367 Issue 2, p124
Background: Hydroxyethyl starch (HES) 130/0.42 is widely used for fluid resuscitation in intensive care units (ICUs), but its safety and efficacy have not been established in patients with severe sepsis. Methods: In this multicenter, parallel-group, blinded trial, we randomly assigned patients...
- Pentastarch resuscitation in severe sepsis and septic shock. Green, Robert S.; Zed, Peter J.; McIntyre, Lauralyn // CJEM: Canadian Journal of Emergency Medicine;Jan2010, Vol. 12 Issue 1, p58
The article focuses on the study concerning the effect of pentastarch resuscitation in treating patients with severe sepsis and septic shock. It says that patients with severe sepsis or septic shock who were administered with pentastarch experienced renal failure. It suggests that emergency...
- Reporting bias in trials of volume resuscitation with hydroxyethyl starch. Wiedermann, Christian J. // Wiener Klinische Wochenschrift;Apr2014, Vol. 126 Issue 7/8, p189
The possibility of renal damage by hydroxyethyl starch has become the focus of intensive dispute based on the findings of published large trials. The aim of this narrative review is to analyze outcome reporting bias in the literature on volume resuscitation, focusing on selective outcome...
- Meta-analyses of Hydroxyethyl Starch for Volume Resuscitation. Ioannidis, John P. A.; Zarychanski, Ryan; Turgeon, Alexis F.; Abou-Setta, Ahmed M. // JAMA: Journal of the American Medical Association;6/5/2013, Vol. 309 Issue 21, p2209
A letter to the editor is presented in response to an article related to the effect of hydroxy-ethyl starch administration in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis" in the previous issue and also presents a response from the authors.
- Hydroxyethyl Starch 130/0.4 versus Ringer's Acetate in Severe Sepsis. // New England Journal of Medicine;8/2/2012, Vol. 367 Issue 5, p481
A correction to the article regarding the hydroxyethyl starch versus ringer's acetate in severe sepsis in the 2012 issue is presented.
- 'Colloid twice daily' is not fluid resuscitation! Inappropriate inclusion of clinical trials in meta-analyses may distract from gaps in evidence. Kranke, Peter; Roewer, Norbert; Muellenbach, Ralf // Intensive Care Medicine;Aug2013, Vol. 39 Issue 8, p1503
A letter to the editor is presented regarding the impact of hydroxyethyl starch for severe sepsis on mortality by A. Patel and colleagues.
- Is 6% tetrastarch 130 kDa (hydroxyethyl starch 130/0.4 or 130/0.42) suitable for severe sepsis? Patel, Amit; Brett, Stephen J. // British Journal of Hospital Medicine (17508460);Mar2013, Vol. 74 Issue 3, p178
The article discusses whether 6% tetrastarch which is used to maintain volume expansion 130 kDa (hydroxyethyl starch130/0.4 or 130/0.42) is suitable for patients with severe sepsis or not. It mentions the two aspects of the study in which one shows the case with 6% tetrastarch 130 kDa in severe...